---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-000894"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-19T23:54:39.042643+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Omeros receives $200M milestone payment from Rayner; 2022 OMIDRIA sales $131M

## Summary
- Rayner paid $200M milestone plus accrued interest on Feb 3, 2023; U.S. royalty rate drops from 50% to 30%.
- Omeros ended 2022 with ~$195M cash; combined with $200M milestone provides funding into at least 2025.
- 2022 U.S. net sales of OMIDRIA totaled $131M; CAA 2023 secures separate payment for non-opioid pain drugs through Jan 2028.
- Proceeds to fund R&D, manufacturing, potential acquisitions; may retire convertible notes.

## SEC filing metadata
- accession: 0001558370-23-000894
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000155837023000894/0001558370-23-000894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000155837023000894/omer-20230206x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-000894
- JSON: https://secwatch.observer/filing/0001558370-23-000894.json
- Plain text: https://secwatch.observer/filing/0001558370-23-000894.txt

## Key facts
- Earnings Releases
  OMEROS CORP reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: U.S. net sales of OMIDRIA in 2022 totaled $131 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285819/000155837023000894/0001558370-23-000894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.